{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:29Z","timestamp":1781179109429,"version":"3.54.1"},"reference-count":27,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Haploidentical transplant (haploSCT) has its own unique complications; hence, we studied the outcome of haploSCT from a cancer hospital in India. We retrospectively analyzed the haploSCTs performed at our center between March 2015 and mid-August 2022 using posttransplant cyclophosphamide (PTCy). Ninety-nine patients (95 malignant and 4 nonmalignant) underwent 101 haploSCTs. Myeloablative (MA), nonmyeloablative (NMA), and reduced intensity conditioning (RIC) were used in 35 (34.6%), 43 (42.5%), and 23 (22.7%) transplants, respectively. The median CD34\u2009+\u2009 was 5.9 (1.8\u201310) \u00d7106\/kg. The median time to neutrophil and platelet engraftment was 15 (11\u201332) and 15.5 (9\u2013120) days, respectively. There were 09 (8.9%) cases of primary graft rejection. Eighteen (17.8%) patients had a relapse. Acute graft versus host disease (GVHD) was observed in 33 (32.6%) cases. Blood cultures were positive in 42 (41.5%) transplants. Common viral infections were BK (47.3%) and cytomegalovirus (CMV; 65.3%). The median follow-up was 6 (0.5\u201389.5) months. Forty-eight (48.4%) patients had died at the last follow-up. The main causes of the death were sepsis (27 [56.2%]), relapse (10 [22.2%]), and GVHD (04 [8.8%]). The nonrelapse mortality was 37.3%. The median overall survival (OS) was 18\u2009\u00b1\u200911.46 (0\u201340.77) months. The 1-year OS was 56.7%, while the 2-year OS was 49.3%. We emphasize that haploSCT offers a reasonable hope of survival for patients, although infections remain a significant challenge based on our experience.<\/jats:p>","DOI":"10.1055\/s-0043-1771274","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:21:10Z","timestamp":1695842470000},"page":"588-596","source":"Crossref","is-referenced-by-count":2,"title":["Haploidentical Stem Cell Transplantation for Hematological Disorders: Real-World Experience from India"],"prefix":"10.25259","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-5369","authenticated-orcid":false,"given":"Pallavi","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvdeep","family":"Khushoo","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"R Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States","volume":"22","author":"J Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"ref3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood.V118.21.833.833","article-title":"T-cell replete haploidentical transplantation using post transplant cyclophosphamide results in equivalent non-relapse mortality and disease-free survival compared to transplantation from HLA-identical sibling and matched unrelated donors: a stratified Cox model analysis of two hundred and sixty contemporaneous allogeneic transplants from a single center","volume":"118","author":"A Bashey","year":"2011","journal-title":"Blood"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"P Armand","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"e0191955","DOI":"10.1371\/journal.pone.0191955","article-title":"Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: a meta-analysis","volume":"13","author":"D Chen","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis","volume":"5","author":"N Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10875-019-00600-z","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in south India","volume":"39","author":"R Uppuluri","year":"2019","journal-title":"J Clin Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1182\/blood-2018-99-118239","article-title":"Haplo-identical transplants using post transplant cyclophosphamide (PTCy) are associated with good outcomes if transplanted with early disease: a single centre analysis from India","volume":"132","author":"B George","year":"2018","journal-title":"Blood"},{"key":"ref9","first-page":"1","article-title":"Review of haploidentical hematopoietic cell transplantation","volume":"4","author":"M A Khan","year":"2018","journal-title":"J Glob Oncol"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"D E Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"S O Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"S Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11912-015-0482-9","article-title":"Haploidentical bone marrow transplantation in 2015 and beyond","volume":"17","author":"G J Ruiz-Arg\u00fcelles","year":"2015","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings","volume":"313","author":"P G Beatty","year":"1985","journal-title":"N Engl J Med"},{"issue":"06","key":"ref15","first-page":"443","article-title":"Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion","volume":"7","author":"R C Ash","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"A Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/bmt.2013.51","article-title":"Hematopoietic SCT in Europe: data and trends in 2011","volume":"48","author":"J R Passweg","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"S O Ciurea","year":"2015","journal-title":"Blood"},{"issue":"25","key":"ref19","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Y Wang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors","volume":"20","author":"A Di Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"ref21","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Y Luo","year":"2014","journal-title":"Blood"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"A S Kanate","year":"2016","journal-title":"Blood"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.bbmt.2014.11.069","article-title":"Developing a haploidentical transplant program: an Indian experience","volume":"21","author":"S Jaiswal","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"A M Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"ref25","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"F Aversa","year":"1998","journal-title":"N Engl J Med"},{"issue":"15","key":"ref26","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"F Aversa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2006.07.0953","article-title":"Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution","volume":"25","author":"D A Rizzieri","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1771274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:10Z","timestamp":1781176390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/haploidentical-stem-cell-transplantation-for-hematological-disorders-real-world-experience-from-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":27,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1771274","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}